Robert L. Coleman
Active 1994–2026
- Also published as
- Robert L Coleman
- 257
- Papers
- 44,230
- Citations
- 107
- h-index
- 248
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine61.9%
- Biochemistry, Genetics and Molecular Biology29.6%
- Immunology and Microbiology2.5%
- Materials Science1.1%
- Neuroscience1.1%
- Engineering1%
- Other2.8%
Topics
- Ovarian cancer diagnosis and treatment7.4%
- PARP inhibition in cancer therapy5.6%
- Endometrial and Cervical Cancer Treatments4.7%
- MicroRNA in disease regulation2%
- Breast Cancer Treatment Studies2%
- HER2/EGFR in Cancer Research2%
- Other76.3%
Coauthors
- Anil K. Sood65
- Bradley J. Monk41
- David M. Gershenson38
- David M. O’Malley37
- Ana Oaknin29
- Kathleen N. Moore29
- Thomas J. Herzog28
- Brian M. Slomovitz27
- Domenica Lorusso25
- Carol Aghajanian24
- Amit M. Oza23
- Shannon N. Westin23
- Elizabeth M. Swisher22
- Isabelle Ray‐Coquard22
- Nicoletta Colombo22
- Alpa M. Nick21
- Ignace Vergote21
- Pedro T. Ramírez21
- Gabriel Lopez‐Berestein17
- Mansoor Raza Mirza17
- Sandra Goble17
- Lara Maloney16
- Aparna A. Kamat14
- Karen H. Lu14
All papers
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Authors: Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, René dePont Christensen, Zoltán Novàk, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M. Landrum, Lars Hanker, Ashley Stuckey, Ingrid Boere, Michael A. Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn K. McCourt, Francesco Raspagliesi, Mark S. Shahin, Sarah Gill, Bradley J. Monk, Joseph Buscema, Thomas J. Herzog, Larry J. Copeland, Min Tian, Zangdong He, Shadi Stevens, Eleftherios Zografos, Robert L. Coleman, Matthew A. Powell - New England Journal of Medicine 2023 cited by 800
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Authors: Josep Garcia, Herbert I. Hurwitz, Alan B. Sandler, David Miles, Robert L. Coleman, Regula Deurloo, Olivier Chinot - Cancer Treatment Reviews 2020 cited by 1,136
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Jesús García-Donás, Elizabeth M. Swisher, Anne Floquet, Gottfried E. Konecny, Iain A. McNeish, Clare L. Scott, T. Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline A. Grace, Thomas C. Harding, Mitch Raponi, James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian and 17 more - The Lancet 2017 cited by 1,704
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Authors: Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method, Robert L. Coleman - Journal of Clinical Oncology 2023 cited by 372
- Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
Authors: Pedro T. Ramírez, Michael Frumovitz, René Pareja, Aldo López, Marcelo de Andrade Vieira, Reitan Ribeiro, Alessandro Buda, Xiaojian Yan, Yao Shuzhong, Naven Chetty, David Isla, Mariano Tamura, Tao Zhu, Kristy Robledo, Val Gebski, Rebecca Asher, Vanessa Behan, James Nicklin, Robert L. Coleman, Andreas Obermair - New England Journal of Medicine 2018 cited by 1,869
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Authors: Bernard Asselain, William E. Barlow, John M.S. Bartlett, Jonas Bergh, Elizabeth Bergsten-Nordström, Judith M. Bliss, Francesco Boccardo, Clare Boddington, Jan Bogaerts, Gianni Bonadonna, Rosie Bradley, Étienne Brain, Jeremy Braybrooke, Philippe Broët, John Bryant, Julie Ann Burrett, David Cameron, Mike Clarke, Alan S. Coates, Robert L. Coleman, Raoul Charles Coombes, Candace R. Correa, Joe Costantino, Jack Cuzick, David N. Danforth, Nancy E. Davidson, Christina Davies, Lucy Davies, Angelo Di Leo, David Dodwell, Mitch Dowsett, Frances Duane, Vaughan Evans, Marianne Ewertz, Bernard Fisher, John Forbes, Leslie G. Ford, J.-C. Gazet, Richard D. Gelber, Lucy Gettins, Luca Gianni, Michael Gnant, Jon Godwin, Aron Goldhirsch, Pamela J. Goodwin, Richard Gray, Daniel F. Hayes, Catherine Hill, James N. Ingle, Reshma Jagsi, R. Jakesz, Sam James, Wolfgang Janni, Hui Liu, Zulian Liu, Caroline Lohrisch, Sibylle Loibl, Liz MacKinnon, Andreas Makris, Eleftherios P. Mamounas, Gurdeep Mannu, Miguel Martín, S. Mathoulin, L. Mauriac, Paul McGale, Theresa McHugh, Philip Morris, Hirofumi Mukai, Larry Norton, Yasuo Ohashi, Ivo A. Olivotto, Soon Young Paik, Hongchao Pan, Richárd Pető, Martine Piccart, Lori J. Pierce, Philip Poortmans, Trevor J. Powles, K.I. Pritchard, Joseph Ragaz, Vinod Raina, Peter M. Ravdin, Simon Read, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Suzy Scholl, Dennis J. Slamon, Lidija Sölkner, Joseph A. Sparano, Seth M. Steinberg, Rosemary Sutcliffe, Sandra M. Swain, Carolyn Taylor, Andrew Tutt, Pinuccia Valagussa, Cornelis J.�H. van de Velde, Jos A. van der Hage, Giuseppe Viale, Gϋnter von Minckwitz and 10 more - The Lancet Oncology 2017 cited by 1,133
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Authors: Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, David M. O’Malley, Ana Oaknin, Michelle Wilson, Robert L. Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkıran, Olga Mikheeva, Oladapo Yeku, Anita Chudecka-Głaz, Michael Schenker, Ramey D. Littell, Tamar Safra, Hung‐Hsueh Chou, Mark A. Morgan, Vít Drochýtek, Joyce N. Barlin, Toon Van Gorp, Frederick R. Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile Catherine Collins, Kathleen N. Moore, Frederik Marmé, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit - Journal of Clinical Oncology 2022 cited by 384
- Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Authors: Premal H. Thaker, Liz Y. Han, Aparna A. Kamat, Jesusa M.G. Arevalo, Rie Takahashi, Chunhua Lu, Nicholas B. Jennings, Guillermo N. Armaiz-Peña, James A. Bankson, Murali Ravoori, William M. Merritt, Yvonne G. Lin, Lingegowda S. Mangala, Tae Jin Kim, Robert L. Coleman, Charles N. Landen, Yang Li, Edward Felix, Ángela Sanguino, Robert A. Newman, Mary Lloyd, David M. Gershenson, Vikas Kundra, Gabriel Lopez‐Berestein, Susan K. Lutgendorf, Steve W. Cole, Anil K. Sood - Nature Medicine 2006 cited by 1,296
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Authors: Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Leslie M. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R. Harris, Margaret S. Smith, Leonardo Nicacio, Melinda Siew Leng Teng, Annouschka Laenen, Reshma Rangwala, Luís Manso, Mansoor Raza Mirza, Bradley J. Monk, Ignace Vergote, Francesco Raspagliesi, Bohuslav Melichar, Lydia Gaba Garcia, Amanda Jackson, Stéphanie Henry, Zdeněk Král, Philipp Harter, Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet Oncology 2021 cited by 394
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Authors: Robert L. Coleman, Gini F. Fleming, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Michael Friedländer, Aikou Okamoto, Kathleen N. Moore, Noa Ben-Baruch, Theresa L. Werner, Noelle Cloven, Ana Oaknin, Paul DiSilvestro, Mark A. Morgan, Joo‐Hyun Nam, Charles A. Leath, Shibani Nicum, Andrea R. Hagemann, Ramey D. Littell, David Cella, Sally Baron‐Hay, Jesús García-Donás, Mika Mizuno, Katherine M. Bell‐McGuinn, Danielle Sullivan, Bruce Allen Bach, Sudipta Bhattacharya, Christine K. Ratajczak, Peter Ansell, Minh H. Dinh, Carol Aghajanian, Michael A. Bookman - New England Journal of Medicine 2019 cited by 929
- Exploring and comparing adverse events between PARP inhibitors
Authors: Christopher J. Lafargue, Graziela Zibetti Dal Molin, Anil K. Sood, Robert L. Coleman - The Lancet Oncology 2019 cited by 479
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Authors: Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, Clare L. Scott, Heidi Giordano, James Sun, Gottfried E. Konecny, Robert L. Coleman, Anna V. Tinker, David M. O’Malley, Rebecca Kristeleit, Ling Ma, Katherine M. Bell‐McGuinn, James D. Brenton, Janiel M. Cragun, Ana Oaknin, Isabelle Ray‐Coquard, Maria I. Harrell, Elaina Mann, Scott H. Kaufmann, Anne Floquet, Alexandra Léary, Thomas C. Harding, Sandra Goble, Lara Maloney, Jeff Isaacson, Andrew R. Allen, Lindsey Rolfe, Roman Yelensky, Mitch Raponi, Iain A. McNeish - The Lancet Oncology 2016 cited by 1,200
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Authors: Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin, Isabelle Ray‐Coquard, Anna V. Tinker, Elena Helman, Marc R. Radke, Carmen Say, Lan-Thanh Vo, Elaina Mann, Jeffrey D. Isaacson, Lara Maloney, David M. O’Malley, Setsuko K. Chambers, Scott H. Kaufmann, Clare L. Scott, Gottfried E. Konecny, Robert L. Coleman, James Sun, Heidi Giordano, James D. Brenton, Thomas C. Harding, Iain A. McNeish, Elizabeth M. Swisher - Cancer Discovery 2018 cited by 432
- Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Authors: David M Gershenson, Austin Miller, William E Brady, James Paul, Karen Carty, William Rodgers, David Millan, Robert L Coleman, Kathleen N Moore, Susana Banerjee, Kate Connolly, Angeles Alvarez Secord, David M O'Malley, Oliver Dorigo, Stephanie Gaillard, Hani Gabra, Brian Slomovitz, Parviz Hanjani, John Farley, Michael Churchman, Ailith Ewing, Robert L Hollis, C Simon Herrington, Helen Q Huang, Lari Wenzel, Charlie Gourley - The Lancet 2022 cited by 222
- openalex_id:w4226022025
Authors: David M. Gershenson, Austin Miller, William E. Brady, James Paul, Karen Carty, William H. Rodgers, David Millan, Robert L. Coleman, Kathleen N. Moore, Susana Banerjee, Kate Connolly, Angeles Alvarez Secord, David M. O’Malley, Oliver Dorigo, Stéphanie Gaillard, Hani Gabra, Brian M. Slomovitz, Parviz Hanjani, John Farley, Michael Churchman, Ailith Ewing, Robb Hollis, C. Simon Herrington, Helen Huang, Lari Wenzel, Charlie Gourley cited by 180
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Authors: Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel - The Lancet Oncology 2017 cited by 602
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Authors: Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Barbara M. Norquist, Elizabeth M. Swisher, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Helen Huang, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Sharon X. Liang, Chenglin Ye, Carlos Bais, Leslie M. Randall, John K. Chan, J. Stuart Ferriss, Robert L. Coleman, Carol Aghajanian, Thomas J. Herzog, Philip J. DiSaia, Larry J. Copeland, Robert S. Mannel, Michael J. Birrer, Bradley J. Monk - Journal of Clinical Oncology 2019 cited by 483
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Authors: Prudence A. Francis, Olivia Pagani, Gini F. Fleming, Barbara Walley, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Eva Ciruelos, Harold J. Burstein, Hervé Bonnefoi, Meritxell Bellet, Silvana Martino, Charles E. Geyer, Matthew P. Goetz, Vered Stearns, Graziella Pinotti, Fabio Puglisi, Simon Spazzapan, Miguel Ángel Climent, Lorenzo Pavesi, Thomas Ruhstaller, Nancy E. Davidson, Robert L. Coleman, Marc Debled, Stefan Buchholz, James N. Ingle, Eric P. Winer, Rudolf Maibach, Manuela Rabaglio, Barbara Ruepp, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan - New England Journal of Medicine 2018 cited by 673
- The forefront of ovarian cancer therapy: update on PARP inhibitors
Authors: Mansoor Raza Mirza, Robert L. Coleman, Antonio González-Martı́n, Kathleen N. Moore, Nicoletta Colombo, Isabelle Ray‐Coquard, Sandro Pignata - Annals of Oncology 2020 cited by 370
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Authors: Olga Kondrashova, Minh Nguyen, Kristy Shield‐Artin, Anna V. Tinker, Nelson N.H. Teng, Maria I. Harrell, Michael J. Kuiper, Gwo‐Yaw Ho, Holly E. Barker, Maria Jasin, Rohit Prakash, Elizabeth M. Kass, Meghan R. Sullivan, Gregory J. Brunette, Kara A. Bernstein, Robert L. Coleman, Anne Floquet, Michael Friedländer, Ganessan Kichenadasse, David M. O’Malley, Amit M. Oza, James Sun, Liliane Robillard, Lara Maloney, David D.L. Bowtell, Heidi Giordano, Matthew J. Wakefield, Scott H. Kaufmann, Andrew D. Simmons, Thomas C. Harding, Mitch Raponi, Iain A. McNeish, Elizabeth M. Swisher, Kevin Lin, Clare L. Scott - Cancer Discovery 2017 cited by 417
- ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer
Authors: Kathleen M. Schmeler, René Pareja, Aldo López Blanco, José Humberto Tavares Guerreiro Fregnani, André Lopes, Myriam Perrotta, Audrey Tieko Tsunoda, David Cantú de León, Lois M. Ramondetta, Tarinee Manchana, David R. Crotzer, Orla McNally, Martin Riege, Giovanni Scambia, Juan Manuel Carvajal, Julián Di Guilmi, Gabriel Jaime Rendón-Pereira, Preetha Ramalingam, Bryan Fellman, Robert L. Coleman, Michael Frumovitz, Pedro T. Ramírez - International Journal of Gynecological Cancer 2021 cited by 230
- Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Authors: Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray‐Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Léary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin Lin, Iain A. McNeish - Nature Communications 2021 cited by 205
- RNA interference in the clinic: challenges and future directions
Authors: Chad V. Pecot, George A. Calin, Robert L. Coleman, Gabriel Lopez‐Berestein, Anil K. Sood - Nature reviews. Cancer 2010 cited by 814
- MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Authors: Bradley J. Monk, Rachel N. Grisham, Susana Banerjee, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero, Peter Vuylsteke, Robert L. Coleman, Felix Hilpert, Amit M. Oza, Anneke M. Westermann, Martin K. Oehler, Sandro Pignata, Carol Aghajanian, Nicoletta Colombo, Esther Drill, David Cibula, Kathleen N. Moore, Janna Christy‐Bittel, Josep M. del Campo, Regina Berger, Christian Marth, Jalid Sehouli, David M. O’Malley, Cristina Churruca, Adam P. Boyd, Gunnar B. Kristensen, Andrew R. Clamp, Isabelle Ray‐Coquard, Ignace Vergote - Journal of Clinical Oncology 2020 cited by 153
